Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 7 | 2026 | 134 | 2.380 |
Why?
|
| Healthcare Disparities | 5 | 2025 | 407 | 2.210 |
Why?
|
| Health Services Accessibility | 4 | 2026 | 591 | 1.750 |
Why?
|
| Vitrectomy | 8 | 2026 | 34 | 1.730 |
Why?
|
| Retinopathy of Prematurity | 2 | 2025 | 12 | 1.630 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 460 | 1.620 |
Why?
|
| Tomography, Optical Coherence | 7 | 2024 | 235 | 1.340 |
Why?
|
| Eye Infections, Bacterial | 4 | 2022 | 11 | 1.160 |
Why?
|
| Ophthalmologists | 3 | 2026 | 4 | 1.160 |
Why?
|
| Scleral Buckling | 3 | 2026 | 4 | 1.130 |
Why?
|
| Rural Population | 3 | 2025 | 223 | 1.090 |
Why?
|
| Cross-Sectional Studies | 13 | 2026 | 2701 | 1.000 |
Why?
|
| Diabetic Retinopathy | 3 | 2024 | 60 | 0.960 |
Why?
|
| Retinal Detachment | 5 | 2026 | 22 | 0.960 |
Why?
|
| Ophthalmology | 3 | 2022 | 27 | 0.950 |
Why?
|
| Epiretinal Membrane | 3 | 2024 | 4 | 0.920 |
Why?
|
| Medicare | 4 | 2022 | 625 | 0.910 |
Why?
|
| Retina | 4 | 2022 | 132 | 0.870 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2025 | 100 | 0.850 |
Why?
|
| Optometrists | 1 | 2022 | 2 | 0.760 |
Why?
|
| Geographic Information Systems | 1 | 2022 | 22 | 0.720 |
Why?
|
| Retinal Telangiectasis | 1 | 2021 | 2 | 0.720 |
Why?
|
| United States | 15 | 2026 | 8093 | 0.710 |
Why?
|
| Glaucoma | 2 | 2022 | 64 | 0.710 |
Why?
|
| Osteochondrodysplasias | 1 | 2021 | 12 | 0.690 |
Why?
|
| Telangiectasis | 1 | 2021 | 7 | 0.690 |
Why?
|
| Retrospective Studies | 18 | 2026 | 6872 | 0.690 |
Why?
|
| Lost to Follow-Up | 2 | 2024 | 7 | 0.660 |
Why?
|
| Macula Lutea | 2 | 2026 | 26 | 0.650 |
Why?
|
| Ranibizumab | 2 | 2022 | 21 | 0.650 |
Why?
|
| Bevacizumab | 2 | 2022 | 60 | 0.630 |
Why?
|
| Chorioretinitis | 1 | 2019 | 2 | 0.620 |
Why?
|
| Syphilis | 1 | 2019 | 25 | 0.600 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 36 | 0.600 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 24 | 0.580 |
Why?
|
| Disease Management | 1 | 2020 | 235 | 0.580 |
Why?
|
| Carteolol | 1 | 2018 | 1 | 0.580 |
Why?
|
| Pandemics | 3 | 2023 | 674 | 0.570 |
Why?
|
| Ocular Hypertension | 1 | 2018 | 10 | 0.570 |
Why?
|
| Macular Degeneration | 1 | 2021 | 195 | 0.550 |
Why?
|
| Endophthalmitis | 3 | 2022 | 16 | 0.540 |
Why?
|
| Humans | 34 | 2026 | 65140 | 0.530 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 500 | 0.530 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2024 | 82 | 0.520 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 463 | 0.510 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 179 | 0.510 |
Why?
|
| Intravitreal Injections | 5 | 2022 | 54 | 0.440 |
Why?
|
| Postoperative Complications | 2 | 2024 | 1326 | 0.430 |
Why?
|
| Infant, Newborn | 3 | 2025 | 1422 | 0.410 |
Why?
|
| Vision Disorders | 3 | 2022 | 69 | 0.400 |
Why?
|
| Socioeconomic Factors | 3 | 2026 | 801 | 0.400 |
Why?
|
| Male | 15 | 2026 | 31047 | 0.390 |
Why?
|
| Endotamponade | 2 | 2024 | 9 | 0.380 |
Why?
|
| Morbidity | 2 | 2021 | 110 | 0.330 |
Why?
|
| Female | 14 | 2026 | 34018 | 0.310 |
Why?
|
| Fee-for-Service Plans | 2 | 2020 | 71 | 0.290 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 555 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2022 | 5792 | 0.250 |
Why?
|
| Retinal Diseases | 1 | 2026 | 34 | 0.230 |
Why?
|
| Aged | 7 | 2024 | 14965 | 0.230 |
Why?
|
| Gestational Age | 1 | 2025 | 193 | 0.220 |
Why?
|
| Urban Population | 1 | 2025 | 200 | 0.210 |
Why?
|
| Laser Coagulation | 2 | 2021 | 16 | 0.210 |
Why?
|
| Silicone Oils | 1 | 2024 | 3 | 0.210 |
Why?
|
| Basement Membrane | 1 | 2024 | 27 | 0.210 |
Why?
|
| Follow-Up Studies | 4 | 2026 | 2483 | 0.200 |
Why?
|
| Equipment Design | 2 | 2024 | 363 | 0.200 |
Why?
|
| Search Engine | 1 | 2022 | 11 | 0.190 |
Why?
|
| Child, Preschool | 3 | 2026 | 2061 | 0.190 |
Why?
|
| Censuses | 1 | 2022 | 18 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 49 | 0.190 |
Why?
|
| Choroid Neoplasms | 1 | 2022 | 22 | 0.180 |
Why?
|
| Authorship | 1 | 2022 | 25 | 0.180 |
Why?
|
| Nevus, Pigmented | 1 | 2022 | 20 | 0.180 |
Why?
|
| Nevus | 1 | 2022 | 23 | 0.180 |
Why?
|
| Ophthalmia, Sympathetic | 1 | 2021 | 1 | 0.180 |
Why?
|
| Uveitis, Posterior | 1 | 2021 | 1 | 0.180 |
Why?
|
| Macular Edema | 1 | 2022 | 24 | 0.180 |
Why?
|
| Retinal Vasculitis | 1 | 2021 | 9 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 234 | 0.170 |
Why?
|
| Pseudophakia | 1 | 2021 | 5 | 0.170 |
Why?
|
| Growth Disorders | 1 | 2021 | 30 | 0.170 |
Why?
|
| Geography | 1 | 2021 | 36 | 0.170 |
Why?
|
| Uveitis | 1 | 2021 | 34 | 0.170 |
Why?
|
| Outpatients | 1 | 2022 | 143 | 0.170 |
Why?
|
| Residence Characteristics | 1 | 2022 | 230 | 0.170 |
Why?
|
| Masks | 1 | 2020 | 20 | 0.160 |
Why?
|
| Eye Diseases | 1 | 2020 | 37 | 0.160 |
Why?
|
| Infant | 2 | 2026 | 1693 | 0.160 |
Why?
|
| Patient Simulation | 1 | 2020 | 67 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 801 | 0.160 |
Why?
|
| Treponema | 1 | 2019 | 1 | 0.160 |
Why?
|
| Penicillins | 1 | 2019 | 32 | 0.150 |
Why?
|
| Reoperation | 1 | 2021 | 302 | 0.150 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 277 | 0.150 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 159 | 0.150 |
Why?
|
| Antibodies, Bacterial | 1 | 2019 | 181 | 0.140 |
Why?
|
| Child | 3 | 2026 | 4607 | 0.140 |
Why?
|
| Melanoma | 1 | 2022 | 333 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 180 | 0.140 |
Why?
|
| Hypertension | 1 | 2024 | 612 | 0.140 |
Why?
|
| Adult | 5 | 2024 | 17358 | 0.140 |
Why?
|
| Acute Disease | 1 | 2019 | 663 | 0.130 |
Why?
|
| Registries | 1 | 2022 | 924 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 408 | 0.130 |
Why?
|
| Bacteria | 1 | 2020 | 336 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Middle Aged | 4 | 2024 | 18273 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 272 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 5614 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 706 | 0.110 |
Why?
|
| Adolescent | 2 | 2026 | 6297 | 0.100 |
Why?
|
| Young Adult | 1 | 2020 | 4809 | 0.080 |
Why?
|
| Specialization | 2 | 2020 | 82 | 0.070 |
Why?
|
| Travel | 1 | 2026 | 44 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 3308 | 0.060 |
Why?
|
| Surgical Instruments | 1 | 2024 | 44 | 0.050 |
Why?
|
| World Health Organization | 1 | 2024 | 35 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2024 | 117 | 0.050 |
Why?
|
| PubMed | 1 | 2022 | 11 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2022 | 22 | 0.050 |
Why?
|
| Steroids | 1 | 2022 | 56 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2022 | 35 | 0.050 |
Why?
|
| Fundus Oculi | 1 | 2022 | 26 | 0.050 |
Why?
|
| Syndrome | 1 | 2022 | 180 | 0.040 |
Why?
|
| Vitreous Body | 1 | 2021 | 31 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2021 | 34 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 213 | 0.040 |
Why?
|
| Emulsions | 1 | 2024 | 493 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2020 | 58 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 262 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 60 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 380 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2019 | 11 | 0.040 |
Why?
|
| Photography | 1 | 2019 | 42 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2019 | 50 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2019 | 63 | 0.040 |
Why?
|
| Sex Factors | 1 | 2022 | 992 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1141 | 0.040 |
Why?
|
| Exercise | 1 | 2024 | 964 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 489 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1586 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1445 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 362 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2620 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3762 | 0.020 |
Why?
|